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Abstract
Background: The transmissible spongiform encephalopathies (TSEs) comprise a group of fatal
degenerative neurological diseases in humans and other mammals. After infection, the cellular prion
protein isoform PrPC is converted to the pathological PrPSC scrapie isoform. The continued
conversion of PrPC to PrPSC requires de novo endogenous PrP synthesis for disease progression.
The human prion protein gene (PRNP) promoter was therefore investigated to identify regulatory
elements that could serve as targets for therapeutic intervention.
Findings: The human prion protein gene (PRNP) promoter from position -1593 to +134 relative
to the putative transcriptional start site (+1) was analyzed by transient transfection in HeLa cells.
Deletions from the 5' end between positions -1593 and -232 yielded little change in activity. A
further 5' deletion at position -90 resulted in a decline in activity to a level of about 30% of the full-
length value. DNase I footprinting of the region between positions -259 and +2 identified two
adjacent protected domains designated as prpA (-116 to -143) and prpB (-147 to -186). Internal
deletions combined with mobility shift electrophoresis and methylation interference assays
indicated the presence of sequence specific nuclear factor complexes that bind to the prpA and
prpB domains and activate expression from the human PRNP promoter in an additive fashion.
Conclusion:  Results from transient transfection, DNase I footprinting, mobility shift
electrophoresis, and methylation interference experiments suggest that two DNase I protected
domains designated as prpA and prpB are binding sites for as yet unidentified regulatory factors
that independently activate expression from the PRNP promoter.
Background
The TSEs comprise a group of fatal degenerative neurolog-
ical diseases in mammals [1]. After infection, the endog-
enous cellular prion protein isoform PrPC is converted to
the pathological PrPSC scrapie isoform. The continued
conversion of PrPC to PrPSC requires de novo PrP synthesis
[2-4]. These observations suggest that a reduction in PRNP
expression could ameliorate the progression of TSEs.
The human PRNP  contains two exons with the ORF
located on exon 2 and the 5' untranslated region of the
mRNA on exon 1 [5]. The PRNP is expressed at varying
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levels in many tissues and it is developmentally regulated
[6,7]. PRNP expression was reported to be upregulated by
copper ions, NGF, hypoxia, and hypoglycemia [8-12]. The
PRNP  promoter region has been characterized for the
bovine, murine, rat, marsupial, and human genes [13-18].
It lacks a TATA box but has a high GC content and con-
tains recognition sequences for numerous transcription
factors [18]. Polymorphisms in the human and bovine
promoters have been linked to increased susceptibility to
prion diseases [19,20]. The human PRNP promoter was
here further analyzed to identify additional regulatory
mechanisms.
Results and Discussion
Transfection with PRNP promoter 5' deletions
The full-length PRNP promoter and its 5' deletions (Fig.
1A and 1B) were transiently transfected into HeLa cells.
Expression from the promoter remained largely
unchanged at full-length levels to position -232 (Bpm I)
relative to the transcriptional start site (+1) [21](Fig. 1C).
A further deletion at position -90 (Afe I) resulted in a sig-
nificant decline in activity to about 30% of the full-length
value (p < 0.0001). Additional statistically highly signifi-
cant decreases in activity were observed at position -17
(Mfe I, p < 0.0001) and +101 (Nar I, p < 0.0001) [Fig. 1C].
These results indicated the presence of a significant acti-
vating domain between position -232 and -90. Additional
domains that are essential for PRNP expression are likely
to exist downstream from position -45. However, these
were not further examined here since they are close to the
transcriptional start site and presumably involve factors
associated with transcriptional initiation.
Other similar transfection studies with PRNP promoter
deletions have yielded alternative results [17,18]. In one
report, variable promoter expression from deletions
between positions -1543 and -284 was observed, suggest-
ing the presence of positive and negative regulatory factors
interacting with that region [17]. The reasons for these
divergent observations may be related to differences in
cell types, reporter systems, and constructs used.
DNase I footprinting
To determine if the region between positions -232 and -90
contains nuclear factor binding sites, a fragment extend-
ing from position -259 to +2 was generated by PCR and 5'
end-labeled on the coding strand. The fragment was incu-
bated with HeLa cell nuclear extract and partially digested
with DNase I. Two prominent adjacent footprints desig-
nated as prpA (-116 to -143) and prpB (-147 and -186)
were identified (Fig. 2).
Mobility shift electrophoresis and methylation 
interference
Mobility shift electrophoresis with double stranded oligo-
nucleotide prpA resulted in three binding complexes des-
ignated as bA1-bA3 (Fig. 3A, lanes 1-3). To determine
binding specificity, mobility shift competition was carried
out with a 20-fold excess of unlabeled oligonucleotides
prpB and prpA. No binding competition was detected
with unlabeled oligonucleotide prpB. In contrast, self-
competition with unlabeled prpA eliminated labeled
Sequence of the PRNP promoter and expression analysis of 5'  deletion constructs Figure 1
Sequence of the PRNP promoter and expression 
analysis of 5' deletion constructs. (A) Schematic repre-
sentation of the PRNP promoter from position -1593 to +134 
relative to the putative transcriptional start site (+1) [21]. 
The positions of relevant restriction sites used for deletion 
analysis are indicated. (B) Sequence of the proximal PRNP 
promoter from position -203 to +1. The positions of rele-
vant restriction sites and nuclear factor binding domains 
prpA and prpB are delineated by brackets. (C) PRPN pro-
moter activities in HeLa cells as determined by transient 
transfection. The full-length (FL) promoter construct (col-
umn 1) represents the sequence from position -1593 to 
+134 as indicated in A. The remaining 5' deletions (columns 
2-10) were introduced at the restriction sites as shown in A 
and B. CAT activities were normalized to identical β-galac-
tosidase activities. The activity of each deletion was 
expressed relative to the activity of the full-length promoter 
construct (100%). Each column shows the average value of 8-
10 independent experiments with standard deviation.BMC Research Notes 2009, 2:178 http://www.biomedcentral.com/1756-0500/2/178
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complex bA2, and partially competed complex bA1. Com-
plex bA3 remained unaffected. This suggested that the fac-
tors that bound to the prpA region were distinct from
those that bound to the prpB region and that complex
bA2 and possibly complex bA1 represented sequence spe-
cific binding. Methylation interference was carried out to
identify DNA contact points and to confirm the specificity
of the binding complexes. Partial interference with the
formation of complex bA2 occurred with three methyl-
ated G residue on the coding strand (Fig 3A, lanes 4-7)
and two G residues on the non-coding strand of oligonu-
cleotide prpA (Fig 3A, lanes 8-10). Complexes bA1 and
bA2 remained unaffected.
Mobility shift electrophoresis with labeled oligonucle-
otide prpB yielded five different binding complexes desig-
nated bB1-bB5. Of these complexes, bB1 and bB2 were
exceedingly faint and complex bB3 was barely detectable.
Mobility shift competition with excess unlabeled oligonu-
cleotide prpA resulted in partial competition with com-
plex bB4. The other complexes remained unaffected. Self-
competition with oligonucleotide prpB completely com-
peted labeled complex bB5 while the other complexes
remained unaffected (Fig. 1B, lanes 1-3). This suggested
that binding complex bB5 was sequence specific for the
prpB region. Competition of prpA with complex bB4 indi-
cated that this complex may share a binding motif com-
mon to both the prpA and prpB sequences. Partial
methylation of domain prpB identified three G residues
on the coding strand with partial (Fig. 3B, lanes 4-9) and
four G residues on the non-coding strand (Fig 3B, lanes
10-15) with complete binding interference for complex
bB5. All other binding complexes were unaffected by G-
methylation.
The methylation interference experiments confirmed the
results obtained by mobility shift electrophoresis. Binding
complex bA2 on domain prpA and complex bB5 on prpB
were sequence specific and they contained specific DNA
contact points, defined by methylated G residues that
interfered with complex formation to the respective
domains.
In other related studies, the DNA binding sites for adja-
cent transcriptional factors YY1 and E4BP4 were charac-
terized on the ovine PRNP promoter [22]. Those binding
sites are conserved between mammalian species and they
are present on the human PRNP promoter between posi-
tions -290 to -258. Consequently, they are located
upstream from the prpA and prpB binding sites described
here. PRNP expression was also found to be upregulated
by SP1 and metal transcription factor-1 (MTF-1) [23].
However, the MTF-1 binding sites are located upstream (-
594) and downstream (-90) from the prpA and prpB
binding sites. Furthermore, while SP1 consensus
DNase I footprinting of a PRNP promoter fragment extending  from position -259 to +2. partial DNase I digestion was car- ried out either with (lane 2) or without (lane 1) HeLa cell  nuclear extract Figure 2
DNase I footprinting of a PRNP promoter fragment 
extending from position -259 to +2. partial DNase I 
digestion was carried out either with (lane 2) or with-
out (lane 1) HeLa cell nuclear extract. A dideoxy 
sequencing reaction with the same primer was included for 
positional reference (lanes 3-6). Two prominent footprints 
separated by three base pairs were designated prpB and 
prpA (brackets). The sequence of the DNase I protected 
domains are shown in the left panel.BMC Research Notes 2009, 2:178 http://www.biomedcentral.com/1756-0500/2/178
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Mobility shift electrophoresis (MSE) and methylation interference (M-I) with 5' end labeled double stranded oligonucleotides  encompassing the sequences of DNase I protected domains prpA and prpB Figure 3
Mobility shift electrophoresis (MSE) and methylation interference (M-I) with 5' end labeled double stranded 
oligonucleotides encompassing the sequences of DNase I protected domains prpA and prpB. (A) MSE with 5' end 
labeled double stranded oligonucleotides encompassing the sequences of domain prpA (lane 1, and lower panel). Brackets 
show binding complexes (bA1-bA3) and the free oligonucleotide (f). Mobility shift competition was performed with a 20-fold 
molar excess of unlabeled oligonucleotide prpB (lane2) and prpA (lane 3). Methylated G residues within domain prpA that par-
tially interfere with binding of complex bA2 on the coding [(C), lanes 4-7] and noncoding [(N), lanes 8-11] strands are indicated 
by arrowheads. Lanes 4 and 8 show the methylation patterns of the free oligonucleotides. Lower panel shows the sequence of 
the double stranded oligonucleotide used and G-residues that interfere with binding to complex bA2. (B) Same as in A except 
that the sequence of DNase I protected domain prpB was used. Mobility shift electrophoresis shows the formation of binding 
complexes bB1-bB5 with sequence-specific competition of complex bB5 (lanes 1-3). The same binding complex also exhibits 
binding interference with indicated methylated G residues (bracket, arrowheads) on coding (lanes 4-9) and noncoding (lanes 
10-15) strands. Lanes 4 and 10 show the methylation patterns of the free oligonucleotides.BMC Research Notes 2009, 2:178 http://www.biomedcentral.com/1756-0500/2/178
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sequences are numerous throughout the PRNP promoter,
they do not overlap with the prpA or prpB motifs. Binding
domain prpB also overlaps with a consensus sequence for
the NF-IL6 (C/EBP) transcriptional regulator [18]. How-
ever, Dlaska and Weiss [24] have presented a DNase I
footprint of NF-IL6 binding to the iNOS promoter and
that footprint has a different configuration from the one
observed here. In addition, the methylated G residues that
interfere with binding to prpB do not overlap with the NF-
IL6 consensus sequence. The 3' end of prpA also partially
overlaps with a recognition sequence for transcription fac-
tor AP-1 [18]. However, binding of AP-1 to this domain is
not supported by methylation interference results (Fig. 3).
This suggests that the factors that bind to domains prpA
and prpB are distinct from those previously described.
Transfections with internal deletions of binding domains 
prpA and prpB
To further investigate the function of binding domains
prpA and prpB, the two domains were internally deleted
within a full-length PRNP promoter construct. Domains
prpA and prpB were either deleted separately (Fig 4, dA
and dB), or they were deleted together (Fig. 4, dAB). These
internal deletions were then analyzed by transient trans-
fection in HeLa cells. Individually deleting binding
domain prpA or prpB, reduced expression from the PRNP
promoter by approximately the same amount to about
43% of the wild-type value (Fig. 4, FL). However, deleting
both domains together had an additive effect and expres-
sion was reduced to less than 20% of the wild type value.
The activity from the 5' deletion terminating at position -
90 (Fig. 4, Afe I) was about 30% of the full-length value.
This construct is devoid of both binding domains prpA
and prpB, but for currently unknown reasons its level of
activity is intermediate between the constructs containing
individual internal deletions of prpA and prpB (43%) and
the combined deletion of both domains (18%) [Fig. 4]. It
is conceivable that additional negative regulatory motifs
exist that are removed in the 5' deletion at position -90.
Overall, these results suggest that binding domain prpA
and prpB act in an additive manner to activate PRNP pro-
moter expression.
Conclusion
A proximal promoter region extending from position -232
to +134 was identified that essentially confers full pro-
moter activity in HeLa cells (Fig. 1). This region contains
two nuclear factor-binding domains designated as prpA
and prpB (Fig. 2). These domains are binding sites for dis-
tinct nuclear factors that are as yet unidentified (Fig. 3).
The two domains independently activate expression from
the PRNP promoter (Fig. 4). How these domains operate
within context of the complete exon-intron structure of
the endogenous PRNP gene or how they function within
a neuronal cell background needs to be further investi-
gated.
Methods
Cell cultures, transfections, and enzyme assays
HeLa cells (ATCC: CCL 2) were grown in DMEM supple-
mented with 5% fetal calf serum. Cells were transfected at
50% confluence with the ExGen 500 (Fermentas) trans-
fection reagent according to the manufacturer's instruc-
tions. CAT and β-galactosidase assays were performed as
described elsewhere [25]. CAT activities were quantitated
with a BioRad GS-250 phosphor imager. The CAT activi-
ties resulting from the APP promoter constructs were nor-
malized to corresponding β-galactosidase activities.
Statistical significance (p-value) between selected final
values was obtained with an unpaired t-test.
Plasmids, promoter constructs, and oligonucleotides
A promoter region of the human PRNP was obtained from
HeLa cell genomic DNA by PCR with primers comple-
mentary to the chromosome 20 genomic sequence from
position 4,605,433 to 4,607,158 [NCBI: NT_011387.8].
The resulting promoter fragment extended from the 3' end
of exon 1 (+134) to upstream position -1593 relative to a
putative transcriptional start site (+1)[21]. Deletions from
Activity of internal deletions within the full-length PRNP (- 1593 to +134) promoter construct (column 1) in HeLa cells Figure 4
Activity of internal deletions within the full-length 
PRNP (-1593 to +134) promoter construct (column 1) 
in HeLa cells. Either binding domain prpA (column 4, dA) 
or prpB (column 5, dB), or both domains (column 6, dAB) 
were internally deleted. Deletions from the 5' end at restric-
tion sites Bpm I (column 2, position -232) and Afe I (column 
3, position -90) are shown for comparison. The activity of 
each deletion was expressed relative to the activity of the 
full-length promoter construct (100%). Each column shows 
the average of at least six independent experiments with 
standard deviation.BMC Research Notes 2009, 2:178 http://www.biomedcentral.com/1756-0500/2/178
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the 5'-end were generated by cutting with restriction
enzymes at the indicated positions (Fig. 1A and 1B). All
PRNP  promoter constructs were analyzed in plasmid
pCAT2bGAL [26]. This expression vector contains the bac-
terial genes CAT and LacZ. The LacZ gene is transcribed
from the β-actin promoter and served as an internal con-
trol for experimental variations. The various PRNP pro-
moter constructs were ligated into the mp18 polycloning
site at the 5' end of the CAT gene. Internal deletions of the
prpA and prpB domains were generated by in vitro muta-
genesis [25,27]. Oligonucleotides were synthesized by
Sigma Genosys or MWG Biotech and gel purified prior to
use.
Nuclear extracts and DNase I footprinting
Nuclear extracts were prepared from HeLa cells grown in
suspension to a density of 5-8 × 105 cells/ml [25]. The
final protein concentration in extracts was 10-15 mg/ml
in buffer D containing 25 mM Hepes, pH 7.6, 100 mM
KCl, 2 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 0.1 mM
PMSF, and 10% glycerol. A promoter fragment extending
from position -259 to +2 was amplified by PCR with a
[32P] end-labeled forward primer complementary to the
promoter sequence from position -259 to -235 and an
unlabeled reverse primer complementary to the sequence
from position -23 to +2. The resulting DNA fragment was
purified by agarose gel electrophoresis in 0.5 × TBE. The
labeled fragment (1 μl, 50 × 103 cpm) was preincubated
with 8 μl of HeLa cell nuclear extract (+) or buffer D (-) in
a total reaction volume of 33 μl as described below for
mobility shift electrophoresis. After 30 min of incubation,
the fragment was partially digested with 10-60 units of
DNase I (Roche) for 10 min at 25°C. The reaction was
stopped by adding 20 mM EDTA and 0.5% SDS, followed
by phenol/chloroform extraction and ethanol precipita-
tion. The dried pellet was solubilized in formamide load-
ing buffer and electrophoresed in a 6% sequencing gel.
Mobility shift electrophoresis and methylation 
interference
Double-stranded oligonucleotides comprising the
sequences containing nuclear factor binding domains
prpA or prpB (Fig. 3) were 5' end-labeled with [γ-32P]ATP
[28]. Binding reactions were assembled with 5 μl of
nuclear extract, 1 μl (50 × 103 cpm) of labeled oligonucle-
otide and 24 μl of buffer containing 40 mM Hepes pH 7.6,
2 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 50 mM KCl,
10% glycerol, supplemented with 2 μg of poly(dI-dC)-
poly(dI-dC) [GE Healthcare]. After 30 min incubation at
25°C, the binding reaction products were separated by
electrophoresis in 1% agarose gels containing 0.5 × TBE at
150 V constant voltage. The gels were dried and analyzed
with a BioRad GS-250 Phosphor Imager. In competition
assays, unlabeled oligonucleotides were premixed with
labeled oligonucleotides at a 20-fold molar excess before
adding them to the binding reaction.
Oligonucleotides comprising the sequences of binding
domains prpA and prpB were partially methylated and 5'
end-labeled on either the coding or non-coding strands as
described [28]. After mobility shift electrophoresis, the
binding complexes (Fig. 3) and the free oligonucleotide
were isolated, cleaved with piperidine and separated on a
20% sequencing gel.
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